earnings
confidence high
sentiment positive
materiality 0.80
Twist Bioscience Q3 FY2022 revenue $56.1M (+60% YoY), raises FY guidance to $203M
Twist Bioscience Corp
2022-Q3 EPS reported
-$3.15
revenue$146,259,000
- Revenue $56.1M (+60% YoY from $35.0M); orders $59.7M (+53% YoY).
- Net loss $60.5M ($1.08/sh) vs $40.0M ($0.82/sh) in prior year.
- Cash, cash equivalents and investments total $527.6M as of June 30, 2022.
- FY2022 revenue guidance raised to $203M from prior outlook.
- Launched Twist MRD Rapid 500 Panel, human monkeypox controls, and expanded EUA for SARS-CoV-2 NGS assay.